Page 305 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

284 PART III Therapeutic Modalities for the Cancer Patient

473. McCleese JK, Bear MD, Fossey SL, et al.: The novel HSP90 inhibi- 491. Tentori L, Leonetti C, Scarsella M, et al.: Systemic administra-
tor STA-1474 exhibits biologic activity against osteosarcoma cell tion of GPI 15427, a novel poly(ADP-ribose) polymerase-1
lines, Int J Cancer 125:2792–2801, 2009. inhibitor, increases the antitumor activity of temozolomide against
VetBooks.ir 474. Massimini M, Palmieri C, De Maria R, et al.: 17-AAG and apop- intracranial melanoma, glioma, lymphoma, Clin Cancer Res 9:
tosis, autophagy, and mitophagy in canine osteosarcoma cell lines,
5370–5379, 2003.
Vet Pathol 54:405–412, 2017.
475. Graner AN, Hellwinkel JE, Lencioni AM, et al.: HSP90 inhibitors 492. Dungey FA, Caldecott KW, Chalmers AJ: Enhanced radiosensitiza-
tion of human glioma cells by combining inhibition of poly(ADP-
in the context of heat shock and the unfolded protein response: ribose) polymerase with inhibition of heat shock protein 90, Mol
effects on a primary canine pulmonary adenocarcinoma cell line, Cancer Ther 8:2243–2254, 2009.
Int J Hyperthermia1–15, 2016. 493. Rivera P, Melin M, Biagi T, et al.: Mammary tumor develop-
476. Clemente-Vicario F, Alvarez CE, Rowell JL, et al.: Human genetic ment in dogs is associated with BRCA1 and BRCA2, Cancer Res
relevance and potent antitumor activity of heat shock protein 90 69:8770–8774, 2009.
inhibition in canine lung adenocarcinoma cell lines, PLoS One 494. Xu D, Grishin NV, Chook YM: NESdb: a database of NES-con-
10:e0142007, 2015. taining CRM1 cargoes, Mol Biol Cell 23:3673–3676, 2012.
477. London CA, Bear MD, McCleese J, et al.: Phase I evaluation of 495. Shen A, Wang Y, Zhao Y, et al.: Expression of CRM1 in human
STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in gliomas and its significance in p27 expression and clinical progno-
dogs with spontaneous cancer, PLoS One 6:e27018, 2011. sis, Neurosurgery 65:153–159, 2009.
478. Fauzee NJ, Pan J, Wang YL: PARP and PARG inhibitors—new 496. Kojima K, Kornblau SM, Ruvolo V, et al.: Prognostic impact
therapeutic targets in cancer treatment, Pathol Oncol Res 16:469– and targeting of CRM1 in acute myeloid leukemia, Blood 121:
478, 2010. 4166–4174, 2013.
479. D’Amours D, Desnoyers S, D’Silva I, et al.: Poly(ADP-ribosyl) 497. Yao Y, Dong Y, Lin F, et al.: The expression of CRM1 is associated
ation reactions in the regulation of nuclear functions, Biochem J with prognosis in human osteosarcoma, Oncol Rep 21:229–235,
342(Pt 2):249–268, 1999. 2009.
480. Hochegger H, Dejsuphong D, Fukushima T, et al.: Parp-1 protects 498. Azmi AS, Aboukameel A, Bao B, et al.: Selective inhibitors of
homologous recombination from interference by Ku and Ligase IV nuclear export block pancreatic cancer cell proliferation and reduce
in vertebrate cells, EMBO J 25:1305–1314, 2006. tumor growth in mice, Gastroenterology 144:447–456, 2013.
481. Plummer R, Jones C, Middleton M, et al.: Phase I study of the 499. Lapalombella R, Sun Q, Williams K, et al.: Selective inhibitors of
poly(ADP-ribose) polymerase inhibitor, AG014699, in combina- nuclear export show that CRM1/XPO1 is a target in chronic lym-
tion with temozolomide in patients with advanced solid tumors, phocytic leukemia, Blood 120:4621–4634, 2012.
Clin Cancer Res 14:7917–7923, 2008. 500. Tai YT, Landesman Y, Acharya C, et al.: CRM1 inhibition induces
482. Plummer R, Stephens P, Aissat-Daudigny L, et al.: Phase 1 dose- tumor cell cytotoxicity and impairs osteoclastogenesis in multiple
escalation study of the PARP inhibitor CEP-9722 as monother- myeloma: molecular mechanisms and therapeutic implications,
apy or in combination with temozolomide in patients with solid Leukemia 28:155–165, 2014.
tumors, Cancer Chemother Pharmacol 74:257–265, 2014. 501. Gravina GL, Mancini A, Sanita P, et al.: KPT-330, a potent and
483. Dent RA, Lindeman GJ, Clemons M, et al.: Phase I trial of the oral selective exportin-1 (XPO-1) inhibitor, shows antitumor effects
PARP inhibitor olaparib in combination with paclitaxel for first- modulating the expression of cyclin D1 and survivin in prostate
or second-line treatment of patients with metastatic triple-negative cancer models, BMC Cancer 15:941, 2015.
breast cancer, Breast Cancer Res 15:R88, 2013. 502. Alexander TB, Lacayo NJ, Choi JK, et al.: Phase I study of
484. De Soto JA, Wang X, Tominaga Y, et al.: The inhibition and treat- selinexor, a selective inhibitor of nuclear export, in combination
ment of breast cancer with poly (ADP-ribose) polymerase (PARP- with fludarabine and cytarabine, in pediatric relapsed or refractory
1) inhibitors, Int J Biol Sci 2:179–185, 2006. acute leukemia, J Clin Oncol 34:4094–4101, 2016.
485. Sandhu SK, Schelman WR, Wilding G, et al.: The poly(ADP- 503. Abdul Razak AR, Mau-Soerensen M, Gabrail NY, et al.: First-in-
ribose) polymerase inhibitor niraparib (MK4827) in BRCA class, first-in-human phase I study of selinexor, a selective inhibitor
mutation carriers and patients with sporadic cancer: a phase 1 dose- of nuclear export, in patients with advanced solid tumors, J Clin
escalation trial, Lancet Oncol 14:882–892, 2013. Oncol 34:4142–4150, 2016.
486. Coleman RL, Sill MW, Bell-McGuinn K, et al.: A phase II evalu- 504. Kuruvilla J, Savona M, Baz R, et al.: Selective inhibition of nuclear
ation of the potent, highly selective PARP inhibitor veliparib in export with selinexor in patients with non-Hodgkin lymphoma,
the treatment of persistent or recurrent epithelial ovarian, fallopian Blood 129:3175–3183, 2017.
tube, or primary peritoneal cancer in patients who carry a germline 505. Breit MN, Kisseberth WC, Bear MD, et al.: Biologic activity of
BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic the novel orally bioavailable selective inhibitor of nuclear export
Oncology Group study, Gynecol Oncol 137:386–391, 2015. (SINE) KPT-335 against canine melanoma cell lines, BMC Vet Res
487. Drew Y, Ledermann J, Hall G, et al.: Phase 2 multicentre trial 10:160, 2014.
investigating intermittent and continuous dosing schedules of 506. London CA, Bernabe LF, Barnard S, et al.: Preclinical evaluation of
the poly(ADP-ribose) polymerase inhibitor rucaparib in germline the novel, orally bioavailable Selective Inhibitor of Nuclear Export
BRCA mutation carriers with advanced ovarian and breast cancer, (SINE) KPT-335 in spontaneous canine cancer: results of a phase I
Br J Cancer 114:723–730, 2016. study, PLoS One 9:e87585, 2014.
488. Albert JM, Cao C, Kim KW, et al.: Inhibition of poly(ADP- 507. Xie Q, Gao CF, Shinomiya N, et al.: Geldanamycins exquisitely
ribose) polymerase enhances cell death and improves tumor inhibit HGF/SF-mediated tumor cell invasion, Oncogene 24:3697–
growth delay in irradiated lung cancer models, Clin Cancer Res 13: 3707, 2005.
3033–3042, 2007. 508. Zagzag D, Nomura M, Friedlander DR, et al.: Geldanamycin
489. Donawho CK, Luo Y, Penning TD, et al.: ABT-888, an orally inhibits migration of glioma cells in vitro: a potential role for
active poly(ADP-ribose) polymerase inhibitor that potentiates hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion,
DNA-damaging agents in preclinical tumor models, Clin Cancer J Cell Physiol 196:394–402, 2003.
Res 13:2728–2737, 2007. 509. Masson-Gadais B, Houle F, Laferriere J, et al.: Integrin alphav-
490. Li M, Threadgill MD, Wang Y, et al.: Poly(ADP-ribose) poly- beta3, requirement for VEGFR2–mediated activation of SAPK2/
merase inhibition down-regulates expression of metastasis- p38 and for Hsp90–dependent phosphorylation of focal adhesion
related genes in CT26 colon carcinoma cells, Pathobiology 76: kinase in endothelial cells activated by VEGF, Cell Stress Chaperones
108–116, 2009g. 8:37–52, 2003.